Momenta Pharmaceuticals, Inc. (MNTA) CEO Craig A. Wheeler Sells 2,601 Shares
Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) CEO Craig A. Wheeler sold 2,601 shares of the company’s stock in a transaction on Friday, February 8th. The stock was sold at an average price of $11.76, for a total transaction of $30,587.76. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
NASDAQ MNTA traded up $0.56 during trading on Monday, hitting $12.76. The company had a trading volume of 554,007 shares, compared to its average volume of 569,954. Momenta Pharmaceuticals, Inc. has a one year low of $9.55 and a one year high of $32.20. The firm has a market capitalization of $1.20 billion, a PE ratio of -10.63 and a beta of 2.04.
MNTA has been the subject of several research reports. Zacks Investment Research upgraded shares of Momenta Pharmaceuticals from a “hold” rating to a “buy” rating and set a $13.00 price objective for the company in a report on Thursday, January 3rd. ValuEngine lowered shares of Momenta Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, November 27th. Piper Jaffray Companies initiated coverage on shares of Momenta Pharmaceuticals in a report on Monday, November 5th. They issued an “overweight” rating and a $35.00 price objective for the company. Stifel Nicolaus set a $39.00 price objective on shares of Momenta Pharmaceuticals and gave the stock a “buy” rating in a report on Wednesday, November 7th. Finally, BidaskClub lowered shares of Momenta Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Saturday, January 12th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and two have given a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average target price of $25.75.
About Momenta Pharmaceuticals
Momenta Pharmaceuticals, Inc, a biotechnology company, focuses on developing generic versions of complex drugs, biosimilars, and novel therapeutics for autoimmune diseases in the United States. The company's complex generics programs include Enoxaparin sodium injection, a generic version of Lovenox that is indicated for the prevention and treatment of deep vein thrombosis, as well as supports the treatment of acute coronary syndromes; GLATOPA, a generic version of once-daily COPAXONE for the treatment of patients with relapsing-remitting multiple sclerosis; and GLATOPA, a generic product candidate for three-times-weekly COPAXONE.
Featured Story: Why is the conference call important?
Receive News & Ratings for Momenta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.